肠易激综合征患者的生物标志物：继续寻找圣杯还是暂且搁置？ - Suppr

Biomarkers in Patients with IBS: Continue the Grail Quest or Give It a Rest?

作者信息

Jin Mauricio, Wang Xiao Jing

机构信息

Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.

出版信息

Dig Dis Sci. 2025 Jun 23. doi: 10.1007/s10620-025-09170-0.

DOI:10.1007/s10620-025-09170-0

PMID:40551057

Abstract

摘要

相似文献

Biomarkers in Patients with IBS: Continue the Grail Quest or Give It a Rest?

Dig Dis Sci. 2025 Jun 23. doi: 10.1007/s10620-025-09170-0.

Study of Antibodies to Cytolethal Distending Toxin B (CdtB) and Antibodies to Vinculin in Patients with Irritable Bowel Syndrome.

F1000Res. 2021 Apr 19;10:303. doi: 10.12688/f1000research.52086.4. eCollection 2021.

Tracking Anti-cytolethal Distending Toxin B and Anti-vinculin Over Time and Their Roles in Symptoms.

Dig Dis Sci. 2025 May 4. doi: 10.1007/s10620-025-09068-x.

Gut microbiota profiles and the role of anti-CdtB and anti-vinculin antibodies in patients with functional gastrointestinal disorders (FGID).

Eur J Clin Invest. 2021 Dec;51(12):e13666. doi: 10.1111/eci.13666. Epub 2021 Aug 24.

Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects.

PLoS One. 2015 May 13;10(5):e0126438. doi: 10.1371/journal.pone.0126438. eCollection 2015.

Circulating Anti-cytolethal Distending Toxin B and Anti-vinculin Antibodies as Biomarkers in Community and Healthcare Populations With Functional Dyspepsia and Irritable Bowel Syndrome.

Clin Transl Gastroenterol. 2019 Jul;10(7):e00064. doi: 10.14309/ctg.0000000000000064.

Clinical experience with the use of anti-CdtB and anti-vinculin antibodies in patients with diarrhea in Mexico.

Rev Gastroenterol Mex. 2016 Oct-Dec;81(4):236-239. doi: 10.1016/j.rgmx.2016.07.001. Epub 2016 Sep 24.

Assessment of Anti-vinculin and Anti-cytolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel Syndrome.

Dig Dis Sci. 2017 Jun;62(6):1480-1485. doi: 10.1007/s10620-017-4585-z. Epub 2017 Apr 27.

A low FODMAP diet plus traditional dietary advice versus a low-carbohydrate diet versus pharmacological treatment in irritable bowel syndrome (CARIBS): a single-centre, single-blind, randomised controlled trial.

Lancet Gastroenterol Hepatol. 2024 Jun;9(6):507-520. doi: 10.1016/S2468-1253(24)00045-1. Epub 2024 Apr 18.

Second-Generation Biomarker Testing for Irritable Bowel Syndrome Using Plasma Anti-CdtB and Anti-Vinculin Levels.

Dig Dis Sci. 2019 Nov;64(11):3115-3121. doi: 10.1007/s10620-019-05684-6. Epub 2019 May 31.

本文引用的文献

Tracking Anti-cytolethal Distending Toxin B and Anti-vinculin Over Time and Their Roles in Symptoms.

Dig Dis Sci. 2025 May 4. doi: 10.1007/s10620-025-09068-x.

Potential Value of Biomarker-Based Approaches for Evaluation and Management of Costly Functional Gastrointestinal Diseases.

Clin Gastroenterol Hepatol. 2023 Sep;21(10):2462-2472. doi: 10.1016/j.cgh.2023.04.030. Epub 2023 May 8.

Irritable bowel syndrome: treatment based on pathophysiology and biomarkers.

Gut. 2023 Mar;72(3):590-599. doi: 10.1136/gutjnl-2022-328515. Epub 2022 Oct 28.

British Society of Gastroenterology guidelines on the management of irritable bowel syndrome.

Gut. 2021 Jul;70(7):1214-1240. doi: 10.1136/gutjnl-2021-324598. Epub 2021 Apr 26.

Diagnosis and Treatment of Irritable Bowel Syndrome: A Review.

JAMA. 2021 Mar 2;325(9):865-877. doi: 10.1001/jama.2020.22532.

ACG Clinical Guideline: Management of Irritable Bowel Syndrome.

Am J Gastroenterol. 2021 Jan 1;116(1):17-44. doi: 10.14309/ajg.0000000000001036.

The overlap between irritable bowel syndrome and organic gastrointestinal diseases.

Lancet Gastroenterol Hepatol. 2021 Feb;6(2):139-148. doi: 10.1016/S2468-1253(20)30212-0. Epub 2020 Nov 13.

Application of metabolomics to the study of irritable bowel syndrome.

Neurogastroenterol Motil. 2020 Jun;32(6):e13884. doi: 10.1111/nmo.13884.

AGA Clinical Practice Guidelines on the Laboratory Evaluation of Functional Diarrhea and Diarrhea-Predominant Irritable Bowel Syndrome in Adults (IBS-D).

Gastroenterology. 2019 Sep;157(3):851-854. doi: 10.1053/j.gastro.2019.07.004. Epub 2019 Jul 11.

Biomarkers as a diagnostic tool for irritable bowel syndrome: where are we?

Expert Rev Gastroenterol Hepatol. 2017 Apr;11(4):303-316. doi: 10.1080/17474124.2017.1288096. Epub 2017 Feb 13.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Biomarkers in Patients with IBS: Continue the Grail Quest or Give It a Rest?

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

本文引用的文献